Trinity Biotech plc (TRIB) Upgraded by Zacks Investment Research to Hold

trinity-biotech-plc-trib-upgraded-by-zacks-investment-research-to-hold.jpg

Trinity Biotech plc (NASDAQ:TRIB) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Friday.
According to Zacks, “Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners. “
Shares of Trinity Biotech plc (NASDAQ:TRIB) opened at 12.96 on Friday. The company has a market capitalization of $298.29 million, a PE ratio of 55.15 and a beta of 0.92. The stock has a 50 day moving average price of $12.76 and a 200 day moving average price of $11.53. Trinity Biotech plc has a 52-week low of $9.20 and a 52-week high of $14.98.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/09/trinity-biotech-plc-trib-upgraded-by-zacks-investment-research-to-hold.html

Trinity Biotech plc (NASDAQ:TRIB) last announced its earnings results on Thursday, July 21st. The company reported $0.09 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.03. The firm earned $26.30 million during the quarter, compared to analyst estimates of $24.30 million. On average, analysts predict that Trinity Biotech plc will post $0.14 earnings per share for the current fiscal year.
Other large investors have recently made changes to their positions in the company. Franklin Street Advisors Inc. NC raised its stake in shares of Trinity Biotech plc by 27.5% in the first quarter. Franklin Street Advisors Inc. NC now owns 25,175 shares of the company’s stock worth $294,000 after buying an additional 5,425 shares in the last quarter. Kimelman & Baird LLC raised its stake in shares of Trinity Biotech plc by 0.6% in the first quarter. Kimelman & Baird LLC now owns 109,367 shares of the company’s stock worth $1,275,000 after buying an additional 675 shares in the last quarter. Granite Investment Partners LLC raised its stake in shares of Trinity Biotech plc by 7.2% in the first quarter. Granite Investment Partners LLC now owns 153,555 shares of the company’s stock worth $1,791,000 after buying an additional 10,288 shares in the last quarter. Skylands Capital LLC raised its stake in shares of Trinity Biotech plc by 6.0% in the first quarter. Skylands Capital LLC now owns 244,350 shares of the company’s stock worth $2,849,000 after buying an additional 13,800 shares in the last quarter. Finally, Adirondack Research & Management Inc. raised its stake in shares of Trinity Biotech plc by 1.3% in the first quarter. Adirondack Research & Management Inc. now owns 415,353 shares of the company’s stock worth $4,843,000 after buying an additional 5,466 shares in the last quarter.
About Trinity Biotech plc
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.

Receive News & Ratings for Trinity Biotech plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Trinity Biotech plc and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Trinity Biotech plc (TRIB) Upgraded by Zacks Investment Research to Hold"

Leave a comment

Your email address will not be published.


*